The safety of bortezomib for the treatment of multiple myeloma

CENGİZ SEVAL G., BEKSAÇ M.

EXPERT OPINION ON DRUG SAFETY, cilt.17, sa.9, ss.953-962, 2018 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 17 Sayı: 9
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1080/14740338.2018.1513487
  • Dergi Adı: EXPERT OPINION ON DRUG SAFETY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.953-962
  • Anahtar Kelimeler: Bortezomib, multiple myeloma, proteasome inhibitor, peripheral neuropathy, PROTEASOME INHIBITOR PS-341, PANOBINOSTAT PLUS BORTEZOMIB, STEM-CELL TRANSPLANTATION, RANDOMIZED PHASE-III, PERIPHERAL NEUROPATHY, OPEN-LABEL, FOLLOW-UP, DEXAMETHASONE, LENALIDOMIDE, SURVIVAL
  • Ankara Üniversitesi Adresli: Evet

Özet

Introduction: There is now 16 years' worth of established results of various trials demonstrating the bortezomib efficiency in the treatment of multiple myeloma. Over this time, the introduction of bortezomib has been a major break through in the treatment of multiple myeloma. Bortezomib can be administered in the outpatient setting with manageable toxicities.